Abstract

The phosphatidylinositol 3-kinase (PI3K)/Akt pathway plays important roles for prostate cancer cell survival, and the androgen receptor (AR) plays essential roles for prostate cancer cell proliferation. How these two signals cooperate to control cell growth and death, however, remains unclear and debated. Here we provide the first linkage by the identification of Forkhead transcription factor FOXO3a, the PI3K/Akt downstream substrate, as a positive regulator for the induction of AR gene expression. Both Western blot and real time PCR assays demonstrate that FOXO3a can induce AR expression at the protein and mRNA levels, and gel shift and chromatin immunoprecipitation assays further demonstrate that FOXO3a can induce 5' AR promoter activity via binding to the consensus DNA-binding sequence in the AR 5' promoter -1290 to -1297 (5'-TTGTTTCA-3'). Under normal growth conditions, blocking PI3K/Akt signals by LY294002 causes LNCaP cell arrest in G1 phase rather than apoptosis. However, further blocking of AR functions by AR small interfering RNA leads to dramatic LNCaP cell death, suggesting that AR may play important protective roles when the PI3K/Akt signal pathway is blocked by LY294002. Together, our data provide the first model to explain how PI3K/Akt and AR can cooperate to control LNCaP cell growth and death under normal conditions.

Highlights

  • Prostate cancer (PCa)3 is one of the most frequently diagnosed malignancies and is the second leading cause of cancer deaths among American men [1]

  • This suggests that inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, the dominant survival factor in prostate cancer LNCaP cells, may result in the activation of the FOXO3a transcription factor, which may induce the androgen receptor (AR) gene expression to protect cells from apoptosis caused by inhibition of PI3K/Akt pathway

  • AR transactivation can be induced by LY294002, a selective PI3K inhibitor, to play a dominant role in cell proliferation to compensate for the loss of PI3K/Akt signaling (9 –11, 15)

Read more

Summary

Introduction

Prostate cancer (PCa)3 is one of the most frequently diagnosed malignancies and is the second leading cause of cancer deaths among American men [1]. This suggests that inhibition of the PI3K/Akt pathway, the dominant survival factor in prostate cancer LNCaP cells, may result in the activation of the FOXO3a transcription factor, which may induce the AR gene expression to protect cells from apoptosis caused by inhibition of PI3K/Akt pathway. Because the chromatin environment modulates transcription factor binding, an issue that cannot be addressed by EMSA, ChIP assays were undertaken to determine whether FOXO3a was bound to the endogenous AR promoter when PI3K/Akt was blocked.

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.